SIMILAR PATTERNS OF AMINO ACIDS FOR 4CKI_A_ADNA2022

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1fot	CAMP-DEPENDENT PROTEIN KINASE TYPE 1 (Saccharomyces cerevisiae)	PF00069 (Pkinase)	6	LEU A 93 GLY A 94 GLY A 96 VAL A 101 ALA A 114 TYR A 166	None	0.62A	4ckiA-1fotA: 24.0	4ckiA-1fotA: 24.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 411 VAL A 416 ALA A 428 TYR A 476 GLY A 480 LEU A 528	None	0.66A	4ckiA-1k2pA: 28.1	4ckiA-1k2pA: 35.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 408 GLY A 411 VAL A 416 TYR A 476 GLY A 480 LEU A 528	None	0.88A	4ckiA-1k2pA: 28.1	4ckiA-1k2pA: 35.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	GLY A 202 VAL A 209 ALA A 220 TYR A 268 GLY A 272 SER A 273 LEU A 321	None	0.38A	4ckiA-1k9aA: 35.1	4ckiA-1k9aA: 26.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1luf	MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK (Rattus norvegicus)	PF07714 (Pkinase_Tyr)	6	GLY A 581 VAL A 588 ALA A 606 TYR A 656 GLY A 660 LEU A 731	None	0.74A	4ckiA-1lufA: 26.8	4ckiA-1lufA: 37.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1py5	TGF-BETA RECEPTOR TYPE I (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	8	GLY A 212 GLY A 214 VAL A 219 ALA A 230 TYR A 282 GLY A 286 SER A 287 LEU A 340	None None PY1 A 700 ( 4.7A) PY1 A 700 (-3.5A) PY1 A 700 (-4.6A) PY1 A 700 (-3.6A) None PY1 A 700 (-4.4A)	0.71A	4ckiA-1py5A: 28.3	4ckiA-1py5A: 25.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 616 GLY A 617 VAL A 624 ALA A 642 TYR A 693 GLY A 697 LEU A 818	None	0.51A	4ckiA-1rjbA: 30.8	4ckiA-1rjbA: 42.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 616 GLY A 831 ALA A 642 TYR A 693 GLY A 697 LEU A 818	None	0.67A	4ckiA-1rjbA: 30.8	4ckiA-1rjbA: 42.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 78 GLY A 79 VAL A 86 ALA A 99 GLY A 153 SER A 154 LEU A 201	ATP A 535 (-3.9A) ATP A 535 ( 3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 4.7A) ATP A 535 (-2.6A) ATP A 535 (-4.8A)	0.57A	4ckiA-1s9iA: 17.0	4ckiA-1s9iA: 26.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 595 GLY A 596 VAL A 603 ALA A 621 TYR A 672 GLY A 676 LEU A 799	STI A 3 ( 3.8A) None STI A 3 ( 4.6A) STI A 3 (-3.5A) STI A 3 ( 4.0A) STI A 3 ( 3.8A) STI A 3 (-4.4A)	0.51A	4ckiA-1t46A: 33.1	4ckiA-1t46A: 45.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1u59	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 344 GLY A 345 VAL A 352 ALA A 367 ALA A 417 GLY A 420 LEU A 468	STU A 100 (-3.8A) STU A 100 (-3.3A) STU A 100 (-4.8A) STU A 100 (-3.2A) STU A 100 (-3.7A) STU A 100 (-3.5A) STU A 100 (-4.5A)	0.58A	4ckiA-1u59A: 34.0	4ckiA-1u59A: 34.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1u5q	SERINE/THREONINE PROTEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	7	GLY A 35 VAL A 42 ALA A 55 TYR A 107 GLY A 110 SER A 111 LEU A 158	None	0.55A	4ckiA-1u5qA: 27.3	4ckiA-1u5qA: 26.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1ua2	CELL DIVISION PROTEIN KINASE 7 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 18 GLY A 19 GLY A 21 VAL A 26 ALA A 39 LEU A 144	ATP A 381 (-4.4A) ATP A 381 ( 3.9A) TPO A 170 (-3.1A) ATP A 381 (-4.0A) ATP A 381 (-3.6A) None	0.72A	4ckiA-1ua2A: 21.7	4ckiA-1ua2A: 24.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 15 GLY A 16 GLY A 18 VAL A 23 ALA A 36 TYR A 86 GLY A 90 LEU A 137	HYM A 400 (-4.2A) HYM A 400 ( 3.8A) HYM A 400 ( 3.7A) HYM A 400 (-4.3A) HYM A 400 (-3.5A) HYM A 400 (-4.7A) None HYM A 400 (-4.5A)	0.74A	4ckiA-1zltA: 25.6	4ckiA-1zltA: 25.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU X 17 GLY X 18 VAL X 25 ALA X 37 TYR X 84 GLY X 88 SER X 89 LEU X 137	STU X 902 (-3.8A) STU X 902 ( 3.7A) STU X 902 ( 4.8A) STU X 902 (-3.1A) STU X 902 (-4.6A) STU X 902 (-3.5A) STU X 902 ( 4.0A) STU X 902 (-4.4A)	0.57A	4ckiA-2dq7X: 35.7	4ckiA-2dq7X: 34.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2gcd	SERINE/THREONINE-PRO TEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	7	GLY A 35 VAL A 42 ALA A 55 TYR A 107 GLY A 110 SER A 111 LEU A 158	STU A 400 (-3.3A) STU A 400 ( 4.8A) STU A 400 (-3.2A) STU A 400 (-4.5A) STU A 400 (-3.4A) STU A 400 (-3.3A) STU A 400 ( 4.6A)	0.59A	4ckiA-2gcdA: 28.2	4ckiA-2gcdA: 26.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	LEU A 273 GLY A 274 VAL A 281 ALA A 293 TYR A 340 GLY A 344 SER A 345 LEU A 393	H8H A 534 (-3.8A) H8H A 534 ( 3.8A) H8H A 534 (-4.4A) H8H A 534 (-3.2A) H8H A 534 (-4.3A) H8H A 534 (-3.3A) H8H A 534 ( 4.5A) H8H A 534 (-4.5A)	0.36A	4ckiA-2h8hA: 30.4	4ckiA-2h8hA: 25.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	LEU A 273 GLY A 274 GLY A 276 VAL A 281 ALA A 293 GLY A 344 SER A 345	QUE A 1 (-3.9A) QUE A 1 ( 4.2A) None QUE A 1 ( 4.8A) QUE A 1 (-3.5A) QUE A 1 (-3.0A) QUE A 1 ( 4.7A)	0.73A	4ckiA-2hckA: 30.1	4ckiA-2hckA: 33.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	LEU A 273 GLY A 274 VAL A 281 ALA A 293 GLY A 344 SER A 345 LEU A 393	QUE A 1 (-3.9A) QUE A 1 ( 4.2A) QUE A 1 ( 4.8A) QUE A 1 (-3.5A) QUE A 1 (-3.0A) QUE A 1 ( 4.7A) QUE A 1 (-4.4A)	0.46A	4ckiA-2hckA: 30.1	4ckiA-2hckA: 33.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hen	EPHRIN TYPE-B RECEPTOR 2 (Mus musculus)	PF07714 (Pkinase_Tyr)	7	GLY A 636 GLY A 638 VAL A 643 ALA A 659 GLY A 713 SER A 714 LEU A 761	ADP A 400 ( 3.9A) ADP A 400 ( 4.0A) ADP A 400 ( 4.4A) ADP A 400 (-3.2A) ADP A 400 ( 4.2A) ADP A 400 (-3.1A) ADP A 400 ( 4.7A)	0.88A	4ckiA-2henA: 26.8	4ckiA-2henA: 34.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 251 GLY A 252 VAL A 259 ALA A 271 GLY A 322 SER A 323 LEU A 371	1BM A 499 ( 3.7A) None 1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) 1BM A 499 (-3.5A) None 1BM A 499 (-4.4A)	0.49A	4ckiA-2hk5A: 30.3	4ckiA-2hk5A: 40.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hw6	MAP KINASE-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 55 GLY A 56 VAL A 63 ALA A 76 GLY A 130 SER A 131 LEU A 177	None	0.47A	4ckiA-2hw6A: 20.4	4ckiA-2hw6A: 28.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 248 GLY A 249 GLY A 383 VAL A 256 ALA A 269 LEU A 370	GIN A 600 ( 4.6A) None None GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-4.7A)	0.79A	4ckiA-2hz0A: 33.5	4ckiA-2hz0A: 38.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 248 GLY A 249 VAL A 256 ALA A 269 GLY A 321 LEU A 370	GIN A 600 ( 4.6A) None GIN A 600 ( 4.7A) GIN A 600 (-3.1A) None GIN A 600 (-4.7A)	0.39A	4ckiA-2hz0A: 33.5	4ckiA-2hz0A: 38.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 251 ALA A 271 TYR A 318 GLY A 322 SER A 323 LEU A 371	None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.7A) 1N8 A 501 ( 3.5A) None 1N8 A 501 ( 4.3A)	0.66A	4ckiA-2og8A: 30.2	4ckiA-2og8A: 40.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 588 GLY A 589 VAL A 596 ALA A 614 TYR A 665 GLY A 669 LEU A 785	None	0.43A	4ckiA-2ogvA: 30.8	4ckiA-2ogvA: 43.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	8	LEU A 344 GLY A 345 GLY A 347 VAL A 352 ALA A 367 ALA A 417 GLY A 420 LEU A 468	ANP A 615 (-4.4A) ANP A 615 ( 4.4A) ANP A 615 (-3.6A) ANP A 615 (-4.5A) ANP A 615 (-3.3A) ANP A 615 (-3.9A) ANP A 615 ( 3.9A) ANP A 615 (-4.7A)	0.77A	4ckiA-2ozoA: 24.0	4ckiA-2ozoA: 22.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	7	LEU A 344 GLY A 345 VAL A 352 ALA A 367 ALA A 417 GLY A 418 LEU A 468	ANP A 615 (-4.4A) ANP A 615 ( 4.4A) ANP A 615 (-4.5A) ANP A 615 (-3.3A) ANP A 615 (-3.9A) ANP A 615 ( 4.0A) ANP A 615 (-4.7A)	1.08A	4ckiA-2ozoA: 24.0	4ckiA-2ozoA: 22.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2phk	PHOSPHORYLASE KINASE (Oryctolagus cuniculus)	PF00069 (Pkinase)	6	LEU A 25 GLY A 26 VAL A 33 ALA A 46 GLY A 109 LEU A 156	ATP A 381 ( 4.3A) ATP A 381 (-3.5A) ATP A 381 (-4.1A) ATP A 381 (-3.5A) None ATP A 381 ( 4.8A)	0.50A	4ckiA-2phkA: 25.9	4ckiA-2phkA: 27.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 487 GLY A 488 VAL A 495 ALA A 515 VAL A 564 TYR A 566 ALA A 567	None	0.88A	4ckiA-2psqA: 38.0	4ckiA-2psqA: 44.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 487 GLY A 490 VAL A 495 ALA A 515 TYR A 566 ALA A 567 GLY A 570	None	1.25A	4ckiA-2psqA: 38.0	4ckiA-2psqA: 44.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 487 GLY A 493 VAL A 495 ALA A 515 VAL A 564 TYR A 566	None	0.92A	4ckiA-2psqA: 38.0	4ckiA-2psqA: 44.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 487 VAL A 495 ALA A 515 VAL A 564 TYR A 566 ALA A 567 GLY A 570 LEU A 633	None	0.46A	4ckiA-2psqA: 38.0	4ckiA-2psqA: 44.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 199 VAL A 204 ALA A 215 GLY A 271 SER A 272 LEU A 328	None ADE A 488 ( 4.9A) ADE A 488 (-3.2A) ADE A 488 ( 4.1A) None ADE A 488 (-4.4A)	0.43A	4ckiA-2qluA: 28.5	4ckiA-2qluA: 23.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qob	EPHRIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 628 GLY A 630 VAL A 635 ALA A 651 GLY A 705 LEU A 753	None None BME A 1 (-4.9A) PTR A 701 ( 4.7A) None None	0.92A	4ckiA-2qobA: 33.6	4ckiA-2qobA: 29.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r2p	EPHRIN TYPE-A RECEPTOR 5 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	GLY A 682 GLY A 684 VAL A 689 ALA A 705 TYR A 755 GLY A 759	None	0.81A	4ckiA-2r2pA: 35.7	4ckiA-2r2pA: 33.13
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r2p	EPHRIN TYPE-A RECEPTOR 5 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	GLY A 682 VAL A 689 ALA A 705 TYR A 755 GLY A 759 LEU A 807	None	0.76A	4ckiA-2r2pA: 35.7	4ckiA-2r2pA: 33.13
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r2p	EPHRIN TYPE-A RECEPTOR 5 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	VAL A 689 ALA A 705 TYR A 755 GLY A 759 SER A 760 LEU A 807	None	0.81A	4ckiA-2r2pA: 35.7	4ckiA-2r2pA: 33.13
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 724 GLY A 725 VAL A 732 ALA A 749 GLY A 802 LEU A 850	GW7 A 1 ( 4.2A) None GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) GW7 A 1 (-3.6A) GW7 A 1 (-4.2A)	0.47A	4ckiA-2r4bA: 31.4	4ckiA-2r4bA: 32.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2wtk	SERINE/THREONINE-PRO TEIN KINASE 11 (Homo sapiens)	PF00069 (Pkinase)	6	LEU C 55 GLY C 56 GLY C 58 VAL C 63 ALA C 76 LEU C 183	ANP C 2 ( 4.4A) ANP C 2 (-3.3A) ANP C 2 (-3.0A) ANP C 2 (-4.2A) ANP C 2 (-3.4A) None	0.83A	4ckiA-2wtkC: 26.4	4ckiA-2wtkC: 26.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2wtk	SERINE/THREONINE-PRO TEIN KINASE 11 (Homo sapiens)	PF00069 (Pkinase)	6	LEU C 55 GLY C 56 VAL C 63 ALA C 76 TYR C 131 LEU C 183	ANP C 2 ( 4.4A) ANP C 2 (-3.3A) ANP C 2 (-4.2A) ANP C 2 (-3.4A) None None	0.53A	4ckiA-2wtkC: 26.4	4ckiA-2wtkC: 26.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2x4f	MYOSIN LIGHT CHAIN KINASE FAMILY MEMBER 4 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 112 GLY A 113 VAL A 120 ALA A 133 TYR A 182 GLY A 186	16X A1374 (-4.1A) 16X A1374 (-3.4A) 16X A1374 (-4.8A) 16X A1374 ( 3.8A) 16X A1374 (-4.1A) 16X A1374 (-4.0A)	0.82A	4ckiA-2x4fA: 24.9	4ckiA-2x4fA: 25.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xik	SERINE/THREONINE PROTEIN KINASE 25 (Homo sapiens)	PF00069 (Pkinase)	8	GLY A 27 GLY A 29 VAL A 34 ALA A 47 TYR A 97 GLY A 101 SER A 102 LEU A 147	J60 A1294 ( 4.1A) J60 A1294 ( 4.5A) J60 A1294 ( 4.9A) J60 A1294 (-3.3A) J60 A1294 (-4.5A) J60 A1294 ( 3.8A) None J60 A1294 (-4.8A)	0.90A	4ckiA-2xikA: 22.9	4ckiA-2xikA: 25.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xk9	CHECKPOINT KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 226 GLY A 227 GLY A 229 VAL A 234 ALA A 247 GLY A 307 LEU A 354	XK9 A1511 (-3.8A) XK9 A1511 ( 4.5A) None XK9 A1511 (-4.8A) XK9 A1511 ( 4.1A) XK9 A1511 ( 3.7A) XK9 A1511 (-4.6A)	0.83A	4ckiA-2xk9A: 21.9	4ckiA-2xk9A: 27.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	6	GLY A 628 VAL A 635 ALA A 651 TYR A 701 GLY A 705 LEU A 753	None Q9G A1898 ( 4.7A) Q9G A1898 (-3.2A) Q9G A1898 (-4.8A) Q9G A1898 ( 3.8A) Q9G A1898 (-4.3A)	0.59A	4ckiA-2xyuA: 27.4	4ckiA-2xyuA: 34.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	6	GLY A 628 VAL A 635 TYR A 701 GLY A 705 SER A 706 LEU A 753	None Q9G A1898 ( 4.7A) Q9G A1898 (-4.8A) Q9G A1898 ( 3.8A) Q9G A1898 ( 4.5A) Q9G A1898 (-4.3A)	0.81A	4ckiA-2xyuA: 27.4	4ckiA-2xyuA: 34.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z2w	WEE1-LIKE PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 306 VAL A 313 ALA A 326 TYR A 378 GLY A 382 SER A 383	770 A 901 ( 4.6A) 770 A 901 ( 4.7A) 770 A 901 (-3.5A) 770 A 901 (-4.2A) 770 A 901 (-3.4A) None	0.65A	4ckiA-2z2wA: 25.6	4ckiA-2z2wA: 25.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 68 GLY A 69 GLY A 71 VAL A 76 ALA A 92 GLY A 147 LEU A 194	STU A 1 (-3.8A) STU A 1 (-3.3A) STU A 1 ( 4.1A) None STU A 1 (-3.3A) STU A 1 ( 3.9A) STU A 1 (-4.6A)	0.85A	4ckiA-2z7rA: 23.3	4ckiA-2z7rA: 29.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2z8c	INSULIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A1002 GLY A1003 GLY A1005 VAL A1010 ALA A1028 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 ( 3.9A) None S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 (-3.3A)	0.18A	4ckiA-2z8cA: 36.0	4ckiA-2z8cA: 40.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	7	LEU A 253 GLY A 254 VAL A 261 ALA A 273 GLY A 325 SER A 326 LEU A 374	None	0.66A	4ckiA-2zv7A: 15.7	4ckiA-2zv7A: 35.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3a62	RIBOSOMAL PROTEIN S6 KINASE BETA-1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 97 GLY A 98 GLY A 100 VAL A 105 ALA A 121 TYR A 174	STU A 400 (-3.8A) STU A 400 (-3.6A) None STU A 400 (-4.9A) STU A 400 (-3.1A) STU A 400 (-4.7A)	0.79A	4ckiA-3a62A: 17.2	4ckiA-3a62A: 26.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	LEU A 487 GLY A 488 GLY A 490 VAL A 495 ALA A 515 VAL A 564 TYR A 566 ALA A 567 GLY A 570 LEU A 633	M33 A1996 (-4.0A) M33 A1996 ( 3.8A) M33 A1996 (-3.0A) M33 A1996 ( 4.7A) M33 A1996 (-3.3A) None M33 A1996 ( 4.7A) M33 A1996 (-3.8A) M33 A1996 ( 4.8A) M33 A1996 (-4.5A)	0.72A	4ckiA-3b2tA: 29.5	4ckiA-3b2tA: 50.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c1x	HEPATOCYTE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A1085 GLY A1087 VAL A1092 ALA A1108 TYR A1159 GLY A1163	None None CKK A1500 ( 4.3A) CKK A1500 (-3.2A) CKK A1500 (-4.5A) CKK A1500 ( 4.5A)	0.90A	4ckiA-3c1xA: 26.5	4ckiA-3c1xA: 31.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 484 GLY A 487 ALA A 512 VAL A 561 TYR A 563 ALA A 564 GLY A 567 LEU A 630	C4F A 1 ( 3.9A) None C4F A 1 (-3.3A) C4F A 1 ( 4.8A) None C4F A 1 (-3.5A) None C4F A 1 (-4.6A)	1.21A	4ckiA-3c4fA: 34.3	4ckiA-3c4fA: 51.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 484 GLY A 487 VAL A 492 ALA A 512 VAL A 561 TYR A 563 ALA A 564 LEU A 630	C4F A 1 ( 3.9A) None None C4F A 1 (-3.3A) C4F A 1 ( 4.8A) None C4F A 1 (-3.5A) C4F A 1 (-4.6A)	1.25A	4ckiA-3c4fA: 34.3	4ckiA-3c4fA: 51.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 484 GLY A 490 VAL A 492 ALA A 512 VAL A 561 TYR A 563 ALA A 564 LEU A 630	C4F A 1 ( 3.9A) None None C4F A 1 (-3.3A) C4F A 1 ( 4.8A) None C4F A 1 (-3.5A) C4F A 1 (-4.6A)	0.78A	4ckiA-3c4fA: 34.3	4ckiA-3c4fA: 51.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 202 VAL A 209 ALA A 220 TYR A 268 GLY A 272 SER A 273 LEU A 321	None	0.38A	4ckiA-3d7uA: 28.7	4ckiA-3d7uA: 35.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3dtc	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 151 VAL A 158 ALA A 169 ALA A 223 GLY A 226 LEU A 275	VIN A6331 (-3.5A) VIN A6331 (-4.7A) VIN A6331 (-3.4A) VIN A6331 (-3.8A) VIN A6331 (-3.4A) VIN A6331 (-4.5A)	0.40A	4ckiA-3dtcA: 26.9	4ckiA-3dtcA: 32.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3eb0	PUTATIVE UNCHARACTERIZED PROTEIN (Cryptosporidium parvum)	PF00069 (Pkinase)	6	LEU A 15 GLY A 16 GLY A 18 VAL A 23 ALA A 36 TYR A 119	DRK A 384 (-3.8A) DRK A 384 ( 4.4A) None None DRK A 384 (-3.5A) DRK A 384 (-4.4A)	0.81A	4ckiA-3eb0A: 23.7	4ckiA-3eb0A: 23.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3fme	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 59 GLY A 60 VAL A 67 ALA A 80 SER A 135 LEU A 186	STU A 1 (-3.8A) STU A 1 (-3.5A) None STU A 1 (-3.4A) STU A 1 (-3.2A) STU A 1 (-4.4A)	0.55A	4ckiA-3fmeA: 17.8	4ckiA-3fmeA: 25.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3fzp	PROTEIN TYROSINE KINASE 2 BETA (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 431 GLY A 432 GLY A 434 VAL A 439 ALA A 455 GLY A 508 LEU A 556	AGS A 999 ( 4.4A) AGS A 999 ( 4.2A) AGS A 999 (-3.0A) AGS A 999 (-4.6A) AGS A 999 (-3.6A) None AGS A 999 (-4.5A)	0.85A	4ckiA-3fzpA: 30.8	4ckiA-3fzpA: 36.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3g2f	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-2 (Homo sapiens)	PF00069 (Pkinase)	8	GLY A 210 GLY A 212 VAL A 217 ALA A 228 TYR A 281 GLY A 285 SER A 286 LEU A 340	ADP A 900 (-3.4A) ADP A 900 (-3.0A) ADP A 900 (-4.3A) ADP A 900 (-3.4A) None ADP A 900 ( 4.2A) ADP A 900 (-3.6A) ADP A 900 (-4.6A)	0.78A	4ckiA-3g2fA: 29.0	4ckiA-3g2fA: 27.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3gbz	KINASE, CMGC CDK (Giardia intestinalis)	PF00069 (Pkinase)	6	LEU A 21 GLY A 22 GLY A 24 VAL A 29 ALA A 42 TYR A 93	None	0.74A	4ckiA-3gbzA: 12.3	4ckiA-3gbzA: 26.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3gbz	KINASE, CMGC CDK (Giardia intestinalis)	PF00069 (Pkinase)	7	LEU A 21 GLY A 24 VAL A 29 ALA A 42 TYR A 93 ALA A 94 LEU A 143	None	0.95A	4ckiA-3gbzA: 12.3	4ckiA-3gbzA: 26.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3h4j	SNF1-LIKE PROTEIN KINASE SSP2 (Schizosaccharomyces pombe)	no annotation	6	LEU B 40 GLY B 41 GLY B 43 VAL B 48 ALA B 61 TYR B 113	None	0.69A	4ckiA-3h4jB: 15.6	4ckiA-3h4jB: 27.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3hdn	SERINE/THREONINE-PRO TEIN KINASE SGK1 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 105 GLY A 107 VAL A 112 ALA A 125 TYR A 178 LEU A 229	None GMG A 1 (-3.3A) None GMG A 1 (-3.4A) GMG A 1 ( 4.9A) GMG A 1 ( 4.9A)	0.86A	4ckiA-3hdnA: 15.5	4ckiA-3hdnA: 25.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 833 GLY A 834 VAL A 841 ALA A 859 VAL A 909 TYR A 911 GLY A 915 LEU A1029	8ST A2001 ( 4.7A) None 8ST A2001 ( 4.6A) 8ST A2001 ( 3.8A) 8ST A2001 (-4.1A) 8ST A2001 (-4.9A) None None	0.68A	4ckiA-3hngA: 32.4	4ckiA-3hngA: 42.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3iec	SERINE/THREONINE-PRO TEIN KINASE MARK2 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	6	GLY A 60 ALA A 80 TYR A 131 ALA A 132 GLY A 135 LEU A 182	None	0.85A	4ckiA-3iecA: 25.8	4ckiA-3iecA: 26.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3iec	SERINE/THREONINE-PRO TEIN KINASE MARK2 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	6	GLY A 60 VAL A 67 ALA A 80 TYR A 131 ALA A 132 LEU A 182	None	0.76A	4ckiA-3iecA: 25.8	4ckiA-3iecA: 26.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3igo	CALMODULIN-DOMAIN PROTEIN KINASE 1 (Cryptosporidium parvum)	PF00069 (Pkinase) PF13499 (EF-hand_7)	6	LEU A 82 GLY A 83 GLY A 85 VAL A 90 ALA A 103 LEU A 205	ANP A 610 ( 4.5A) ANP A 610 (-3.5A) ANP A 610 (-2.9A) ANP A 610 (-3.9A) ANP A 610 ( 3.7A) None	0.78A	4ckiA-3igoA: 20.0	4ckiA-3igoA: 19.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3kex	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 696 GLY A 697 VAL A 704 TYR A 770 GLY A 774 SER A 775 LEU A 822	ANP A 1 (-4.4A) ANP A 1 (-3.7A) ANP A 1 (-3.9A) ANP A 1 (-4.3A) ANP A 1 ( 4.9A) None ANP A 1 (-4.7A)	0.75A	4ckiA-3kexA: 28.9	4ckiA-3kexA: 28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lj0	SERINE/THREONINE-PRO TEIN KINASE/ENDORIBONUCLE ASE IRE1 (Saccharomyces cerevisiae)	PF00069 (Pkinase) PF06479 (Ribonuc_2-5A)	6	LEU A 680 GLY A 681 GLY A 683 VAL A 689 ALA A 700 LEU A 804	ADP A2101 ( 4.1A) ADP A2101 (-3.6A) ADP A2101 (-3.3A) ADP A2101 (-4.5A) ADP A2101 (-3.5A) ADP A2101 (-4.4A)	0.73A	4ckiA-3lj0A: 25.4	4ckiA-3lj0A: 23.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lm5	SERINE/THREONINE-PRO TEIN KINASE 17B (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 39 GLY A 40 VAL A 47 ALA A 60 TYR A 112 ALA A 113 GLY A 116 LEU A 165	QUE A 1 ( 3.8A) None QUE A 1 ( 4.6A) QUE A 1 (-3.2A) QUE A 1 (-4.9A) QUE A 1 (-3.9A) None None	0.79A	4ckiA-3lm5A: 25.5	4ckiA-3lm5A: 25.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lw0	INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A1005 GLY A1006 GLY A1008 VAL A1013 ALA A1031 GLY A1085	None	0.62A	4ckiA-3lw0A: 30.3	4ckiA-3lw0A: 39.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ma6	CALMODULIN-DOMAIN PROTEIN KINASE 1 (Toxoplasma gondii)	PF00069 (Pkinase)	6	LEU A 40 GLY A 41 GLY A 43 VAL A 48 ALA A 61 LEU A 164	DXR A 299 ( 4.3A) DXR A 299 ( 4.2A) DXR A 299 ( 4.1A) DXR A 299 (-4.3A) DXR A 299 ( 3.9A) None	0.83A	4ckiA-3ma6A: 22.1	4ckiA-3ma6A: 27.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdy	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (Homo sapiens)	PF07714 (Pkinase_Tyr) PF08515 (TGF_beta_GS)	8	GLY A 211 GLY A 213 VAL A 218 ALA A 229 TYR A 281 GLY A 285 SER A 286 LEU A 339	LDN A 1 ( 4.7A) LDN A 1 ( 4.4A) LDN A 1 ( 4.8A) LDN A 1 (-3.6A) LDN A 1 ( 4.8A) LDN A 1 (-3.3A) None LDN A 1 (-4.5A)	0.72A	4ckiA-3mdyA: 29.0	4ckiA-3mdyA: 26.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mtl	CELL DIVISION PROTEIN KINASE 16 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 171 GLY A 172 VAL A 179 ALA A 192 TYR A 242 LEU A 293	FEF A 668 ( 3.8A) FEF A 668 ( 4.2A) FEF A 668 (-4.9A) FEF A 668 (-3.3A) FEF A 668 (-4.7A) FEF A 668 (-4.2A)	0.54A	4ckiA-3mtlA: 22.4	4ckiA-3mtlA: 24.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mvj	CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 49 GLY A 50 VAL A 57 ALA A 70 TYR A 122 GLY A 126 LEU A 173	XFE A 351 (-4.2A) XFE A 351 ( 4.0A) XFE A 351 ( 4.5A) XFE A 351 (-3.2A) None None XFE A 351 (-4.6A)	0.69A	4ckiA-3mvjA: 25.7	4ckiA-3mvjA: 24.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 209 VAL A 216 ALA A 227 TYR A 279 GLY A 283 SER A 284 LEU A 337	None LDN A 600 (-4.5A) LDN A 600 (-3.2A) LDN A 600 (-4.7A) LDN A 600 (-3.3A) None LDN A 600 (-4.6A)	0.81A	4ckiA-3my0A: 27.4	4ckiA-3my0A: 24.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nie	MAP2 KINASE (Plasmodium falciparum)	PF00069 (Pkinase)	6	GLY A 37 GLY A 39 VAL A 44 ALA A 57 ALA A 114 LEU A 163	ANP A 430 (-3.5A) ANP A 430 (-3.0A) ANP A 430 (-4.2A) ANP A 430 (-3.5A) ANP A 430 (-3.9A) ANP A 430 (-4.4A)	0.76A	4ckiA-3nieA: 23.9	4ckiA-3nieA: 22.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 88 GLY A 89 GLY A 91 VAL A 96 ALA A 109 TYR A 161 ALA A 162 LEU A 212	JOZ A 361 (-4.1A) JOZ A 361 ( 4.3A) SO4 A 5 ( 4.4A) JOZ A 361 ( 4.7A) JOZ A 361 (-3.4A) None JOZ A 361 (-3.8A) None	0.81A	4ckiA-3nuuA: 26.8	4ckiA-3nuuA: 27.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 88 GLY A 89 VAL A 96 ALA A 109 TYR A 161 ALA A 162 GLY A 165 LEU A 212	JOZ A 361 (-4.1A) JOZ A 361 ( 4.3A) JOZ A 361 ( 4.7A) JOZ A 361 (-3.4A) None JOZ A 361 (-3.8A) None None	0.74A	4ckiA-3nuuA: 26.8	4ckiA-3nuuA: 27.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	LEU A 192 GLY A 193 GLY A 195 VAL A 200 ALA A 213 GLY A 269 LEU A 318	AMP A 577 ( 4.3A) AMP A 577 ( 3.7A) AMP A 577 (-3.4A) AMP A 577 (-4.3A) AMP A 577 (-3.4A) None AMP A 577 (-4.8A)	0.75A	4ckiA-3nyoA: 26.0	4ckiA-3nyoA: 21.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 726 GLY A 727 GLY A 729 VAL A 734 ALA A 751 GLY A 804 LEU A 852	03Q A 1 (-3.8A) None 03Q A 1 (-3.3A) 03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 ( 3.9A) 03Q A 1 (-4.4A)	0.51A	4ckiA-3pp0A: 34.5	4ckiA-3pp0A: 31.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	7	GLY A 558 VAL A 565 ALA A 576 TYR A 627 GLY A 631 SER A 632 LEU A 683	STU A 1 (-3.2A) STU A 1 (-4.9A) STU A 1 (-3.3A) STU A 1 (-4.4A) STU A 1 (-3.2A) STU A 1 ( 4.3A) STU A 1 (-4.3A)	0.61A	4ckiA-3ppzA: 32.1	4ckiA-3ppzA: 32.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q4t	ACTIVIN RECEPTOR TYPE-2A (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 201 VAL A 206 ALA A 217 GLY A 273 SER A 274 LEU A 329	None TAK A 2 ( 4.9A) TAK A 2 (-3.5A) TAK A 2 (-3.6A) None TAK A 2 (-4.6A)	0.48A	4ckiA-3q4tA: 28.0	4ckiA-3q4tA: 23.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3qa8	MGC80376 PROTEIN (Xenopus laevis)	PF00069 (Pkinase)	6	LEU A 21 GLY A 22 GLY A 24 VAL A 29 ALA A 42 TYR A 98	None	0.87A	4ckiA-3qa8A: 19.5	4ckiA-3qa8A: 18.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3she	MAP KINASE-ACTIVATED PROTEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 50 GLY A 51 GLY A 53 VAL A 58 ALA A 71 LEU A 173	I85 A 350 (-3.7A) I85 A 350 (-3.5A) I85 A 350 (-3.1A) I85 A 350 (-4.9A) I85 A 350 (-3.3A) None	0.88A	4ckiA-3sheA: 20.9	4ckiA-3sheA: 25.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3sxf	CALMODULIN-DOMAIN PROTEIN KINASE 1 (Toxoplasma gondii)	PF00069 (Pkinase) PF13499 (EF-hand_7)	6	LEU A 57 GLY A 58 GLY A 60 VAL A 65 ALA A 78 LEU A 181	BK5 A 701 ( 4.2A) BK5 A 701 ( 3.8A) BK5 A 701 ( 4.6A) BK5 A 701 (-4.2A) BK5 A 701 (-3.4A) None	0.65A	4ckiA-3sxfA: 22.0	4ckiA-3sxfA: 20.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 423 GLY A 424 GLY A 426 VAL A 431 ALA A 443 TYR A 491 GLY A 495 LEU A 543	PP2 A 1 (-4.1A) PP2 A 1 ( 4.1A) PP2 A 1 ( 4.8A) PP2 A 1 (-4.5A) PP2 A 1 (-3.2A) PP2 A 1 ( 4.9A) PP2 A 1 ( 4.2A) PP2 A 1 (-4.6A)	0.53A	4ckiA-3sxsA: 33.6	4ckiA-3sxsA: 35.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 484 GLY A 485 GLY A 487 VAL A 492 ALA A 512 VAL A 561 TYR A 563	07J A 1 ( 4.3A) 07J A 1 ( 4.9A) None 07J A 1 (-4.0A) 07J A 1 (-3.5A) 07J A 1 (-4.7A) 07J A 1 (-4.7A)	0.78A	4ckiA-3tt0A: 34.0	4ckiA-3tt0A: 48.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 484 GLY A 485 VAL A 492 ALA A 512 VAL A 561 TYR A 563 ALA A 564 GLY A 567 LEU A 630	07J A 1 ( 4.3A) 07J A 1 ( 4.9A) 07J A 1 (-4.0A) 07J A 1 (-3.5A) 07J A 1 (-4.7A) 07J A 1 (-4.7A) 07J A 1 (-3.8A) 07J A 1 (-3.7A) 07J A 1 ( 4.4A)	0.67A	4ckiA-3tt0A: 34.0	4ckiA-3tt0A: 48.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ulz	BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	8	LEU A 295 GLY A 296 GLY A 298 VAL A 303 ALA A 315 TYR A 365 GLY A 369 LEU A 423	None	1.14A	4ckiA-3ulzA: 26.4	4ckiA-3ulzA: 27.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ulz	BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	8	LEU A 295 GLY A 296 VAL A 303 ALA A 315 TYR A 365 GLY A 369 SER A 370 LEU A 423	None	0.74A	4ckiA-3ulzA: 26.4	4ckiA-3ulzA: 27.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3v5q	NT-3 GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 544 VAL A 552 ALA A 570 TYR A 619 GLY A 623 LEU A 686	0F4 A 902 ( 4.2A) None 0F4 A 902 (-3.2A) 0F4 A 902 (-4.2A) 0F4 A 902 (-3.4A) 0F4 A 902 (-4.5A)	0.43A	4ckiA-3v5qA: 30.0	4ckiA-3v5qA: 37.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3vid	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 840 GLY A 841 VAL A 848 ALA A 866 VAL A 916 GLY A 922 LEU A1035	4TT A2001 ( 4.0A) 4TT A2001 ( 4.8A) 4TT A2001 ( 4.5A) 4TT A2001 (-3.5A) None 4TT A2001 (-3.7A) 4TT A2001 (-4.8A)	0.61A	4ckiA-3vidA: 32.0	4ckiA-3vidA: 42.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 59 GLY A 60 VAL A 67 ALA A 80 SER A 135 LEU A 186	None ANK A 401 (-3.4A) ANK A 401 (-4.3A) ANK A 401 (-3.0A) ANK A 401 (-3.7A) ANK A 401 ( 4.9A)	0.87A	4ckiA-3vn9A: 22.1	4ckiA-3vn9A: 24.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3w18	AURORA KINASE A (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 139 GLY A 140 VAL A 147 ALA A 160 TYR A 212 ALA A 213 GLY A 216 LEU A 263	N13 A 501 (-3.7A) None N13 A 501 ( 4.7A) N13 A 501 ( 4.1A) N13 A 501 (-4.4A) N13 A 501 (-3.7A) N13 A 501 (-3.5A) N13 A 501 (-4.5A)	0.70A	4ckiA-3w18A: 22.6	4ckiA-3w18A: 26.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 75 GLY A 76 GLY A 78 VAL A 83 ALA A 96 GLY A 150 SER A 151	ANP A 401 (-3.8A) ANP A 401 ( 3.7A) ANP A 401 (-3.3A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 ( 4.3A) ANP A 401 (-3.3A)	0.84A	4ckiA-3wigA: 22.5	4ckiA-3wigA: 26.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 75 GLY A 76 VAL A 83 ALA A 96 GLY A 150 SER A 151 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 3.7A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 ( 4.3A) ANP A 401 (-3.3A) ANP A 401 (-4.8A)	0.56A	4ckiA-3wigA: 22.5	4ckiA-3wigA: 26.27

[["4CKI_A_ADNA2022_1","1fot","Saccharomyces cerevisiae","CAMP-DEPENDENT PROTEIN KINASE TYPE 1","PF00069(Pkinase)",6,"LEU A  93;GLY A  94;GLY A  96;VAL A 101;ALA A 114;TYR A 166","None","0.62A","4ckiA-1fotA:24.0","4ckiA-1fotA:24.40"],["4CKI_A_ADNA2022_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",6,"GLY A 411;VAL A 416;ALA A 428;TYR A 476;GLY A 480;LEU A 528","None","0.66A","4ckiA-1k2pA:28.1","4ckiA-1k2pA:35.06"],["4CKI_A_ADNA2022_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",6,"LEU A 408;GLY A 411;VAL A 416;TYR A 476;GLY A 480;LEU A 528","None","0.88A","4ckiA-1k2pA:28.1","4ckiA-1k2pA:35.06"],["4CKI_A_ADNA2022_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"GLY A 202;VAL A 209;ALA A 220;TYR A 268;GLY A 272;SER A 273;LEU A 321","None","0.38A","4ckiA-1k9aA:35.1","4ckiA-1k9aA:26.95"],["4CKI_A_ADNA2022_1","1luf","Rattus norvegicus","MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK","PF07714(Pkinase_Tyr)",6,"GLY A 581;VAL A 588;ALA A 606;TYR A 656;GLY A 660;LEU A 731","None","0.74A","4ckiA-1lufA:26.8","4ckiA-1lufA:37.43"],["4CKI_A_ADNA2022_1","1py5","Homo sapiens","TGF-BETA RECEPTOR TYPE I","PF00069(Pkinase);PF08515(TGF_beta_GS)",8,"GLY A 212;GLY A 214;VAL A 219;ALA A 230;TYR A 282;GLY A 286;SER A 287;LEU A 340","None;None;PY1 A 700 ( 4.7A);PY1 A 700 (-3.5A);PY1 A 700 (-4.6A);PY1 A 700 (-3.6A);None;PY1 A 700 (-4.4A)","0.71A","4ckiA-1py5A:28.3","4ckiA-1py5A:25.78"],["4CKI_A_ADNA2022_1","1rjb","Homo sapiens","FL CYTOKINE RECEPTOR","PF07714(Pkinase_Tyr)",7,"LEU A 616;GLY A 617;VAL A 624;ALA A 642;TYR A 693;GLY A 697;LEU A 818","None","0.51A","4ckiA-1rjbA:30.8","4ckiA-1rjbA:42.77"],["4CKI_A_ADNA2022_1","1rjb","Homo sapiens","FL CYTOKINE RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 616;GLY A 831;ALA A 642;TYR A 693;GLY A 697;LEU A 818","None","0.67A","4ckiA-1rjbA:30.8","4ckiA-1rjbA:42.77"],["4CKI_A_ADNA2022_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",7,"LEU A  78;GLY A  79;VAL A  86;ALA A  99;GLY A 153;SER A 154;LEU A 201","ATP A 535 (-3.9A);ATP A 535 ( 3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 4.7A);ATP A 535 (-2.6A);ATP A 535 (-4.8A)","0.57A","4ckiA-1s9iA:17.0","4ckiA-1s9iA:26.26"],["4CKI_A_ADNA2022_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",7,"LEU A 595;GLY A 596;VAL A 603;ALA A 621;TYR A 672;GLY A 676;LEU A 799","STI A   3 ( 3.8A);None;STI A   3 ( 4.6A);STI A   3 (-3.5A);STI A   3 ( 4.0A);STI A   3 ( 3.8A);STI A   3 (-4.4A)","0.51A","4ckiA-1t46A:33.1","4ckiA-1t46A:45.57"],["4CKI_A_ADNA2022_1","1u59","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF07714(Pkinase_Tyr)",7,"LEU A 344;GLY A 345;VAL A 352;ALA A 367;ALA A 417;GLY A 420;LEU A 468","STU A 100 (-3.8A);STU A 100 (-3.3A);STU A 100 (-4.8A);STU A 100 (-3.2A);STU A 100 (-3.7A);STU A 100 (-3.5A);STU A 100 (-4.5A)","0.58A","4ckiA-1u59A:34.0","4ckiA-1u59A:34.38"],["4CKI_A_ADNA2022_1","1u5q","Rattus norvegicus","SERINE\/THREONINE PROTEIN KINASE TAO2","PF00069(Pkinase)",7,"GLY A  35;VAL A  42;ALA A  55;TYR A 107;GLY A 110;SER A 111;LEU A 158","None","0.55A","4ckiA-1u5qA:27.3","4ckiA-1u5qA:26.24"],["4CKI_A_ADNA2022_1","1ua2","Homo sapiens","CELL DIVISION PROTEIN KINASE 7","PF00069(Pkinase)",6,"LEU A  18;GLY A  19;GLY A  21;VAL A  26;ALA A  39;LEU A 144","ATP A 381 (-4.4A);ATP A 381 ( 3.9A);TPO A 170 (-3.1A);ATP A 381 (-4.0A);ATP A 381 (-3.6A);None","0.72A","4ckiA-1ua2A:21.7","4ckiA-1ua2A:24.56"],["4CKI_A_ADNA2022_1","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",8,"LEU A  15;GLY A  16;GLY A  18;VAL A  23;ALA A  36;TYR A  86;GLY A  90;LEU A 137","HYM A 400 (-4.2A);HYM A 400 ( 3.8A);HYM A 400 ( 3.7A);HYM A 400 (-4.3A);HYM A 400 (-3.5A);HYM A 400 (-4.7A);None;HYM A 400 (-4.5A)","0.74A","4ckiA-1zltA:25.6","4ckiA-1zltA:25.22"],["4CKI_A_ADNA2022_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",8,"LEU X  17;GLY X  18;VAL X  25;ALA X  37;TYR X  84;GLY X  88;SER X  89;LEU X 137","STU X 902 (-3.8A);STU X 902 ( 3.7A);STU X 902 ( 4.8A);STU X 902 (-3.1A);STU X 902 (-4.6A);STU X 902 (-3.5A);STU X 902 ( 4.0A);STU X 902 (-4.4A)","0.57A","4ckiA-2dq7X:35.7","4ckiA-2dq7X:34.80"],["4CKI_A_ADNA2022_1","2gcd","Rattus norvegicus","SERINE\/THREONINE-PROTEIN KINASE TAO2","PF00069(Pkinase)",7,"GLY A  35;VAL A  42;ALA A  55;TYR A 107;GLY A 110;SER A 111;LEU A 158","STU A 400 (-3.3A);STU A 400 ( 4.8A);STU A 400 (-3.2A);STU A 400 (-4.5A);STU A 400 (-3.4A);STU A 400 (-3.3A);STU A 400 ( 4.6A)","0.59A","4ckiA-2gcdA:28.2","4ckiA-2gcdA:26.06"],["4CKI_A_ADNA2022_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"LEU A 273;GLY A 274;VAL A 281;ALA A 293;TYR A 340;GLY A 344;SER A 345;LEU A 393","H8H A 534 (-3.8A);H8H A 534 ( 3.8A);H8H A 534 (-4.4A);H8H A 534 (-3.2A);H8H A 534 (-4.3A);H8H A 534 (-3.3A);H8H A 534 ( 4.5A);H8H A 534 (-4.5A)","0.36A","4ckiA-2h8hA:30.4","4ckiA-2h8hA:25.14"],["4CKI_A_ADNA2022_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"LEU A 273;GLY A 274;GLY A 276;VAL A 281;ALA A 293;GLY A 344;SER A 345","QUE A   1 (-3.9A);QUE A   1 ( 4.2A);None;QUE A   1 ( 4.8A);QUE A   1 (-3.5A);QUE A   1 (-3.0A);QUE A   1 ( 4.7A)","0.73A","4ckiA-2hckA:30.1","4ckiA-2hckA:33.86"],["4CKI_A_ADNA2022_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"LEU A 273;GLY A 274;VAL A 281;ALA A 293;GLY A 344;SER A 345;LEU A 393","QUE A   1 (-3.9A);QUE A   1 ( 4.2A);QUE A   1 ( 4.8A);QUE A   1 (-3.5A);QUE A   1 (-3.0A);QUE A   1 ( 4.7A);QUE A   1 (-4.4A)","0.46A","4ckiA-2hckA:30.1","4ckiA-2hckA:33.86"],["4CKI_A_ADNA2022_1","2hen","Mus musculus","EPHRIN TYPE-B RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"GLY A 636;GLY A 638;VAL A 643;ALA A 659;GLY A 713;SER A 714;LEU A 761","ADP A 400 ( 3.9A);ADP A 400 ( 4.0A);ADP A 400 ( 4.4A);ADP A 400 (-3.2A);ADP A 400 ( 4.2A);ADP A 400 (-3.1A);ADP A 400 ( 4.7A)","0.88A","4ckiA-2henA:26.8","4ckiA-2henA:34.06"],["4CKI_A_ADNA2022_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",7,"LEU A 251;GLY A 252;VAL A 259;ALA A 271;GLY A 322;SER A 323;LEU A 371","1BM A 499 ( 3.7A);None;1BM A 499 ( 4.8A);1BM A 499 (-3.6A);1BM A 499 (-3.5A);None;1BM A 499 (-4.4A)","0.49A","4ckiA-2hk5A:30.3","4ckiA-2hk5A:40.07"],["4CKI_A_ADNA2022_1","2hw6","Homo sapiens","MAP KINASE-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 1","PF00069(Pkinase)",7,"LEU A  55;GLY A  56;VAL A  63;ALA A  76;GLY A 130;SER A 131;LEU A 177","None","0.47A","4ckiA-2hw6A:20.4","4ckiA-2hw6A:28.28"],["4CKI_A_ADNA2022_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",6,"LEU A 248;GLY A 249;GLY A 383;VAL A 256;ALA A 269;LEU A 370","GIN A 600 ( 4.6A);None;None;GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-4.7A)","0.79A","4ckiA-2hz0A:33.5","4ckiA-2hz0A:38.39"],["4CKI_A_ADNA2022_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",6,"LEU A 248;GLY A 249;VAL A 256;ALA A 269;GLY A 321;LEU A 370","GIN A 600 ( 4.6A);None;GIN A 600 ( 4.7A);GIN A 600 (-3.1A);None;GIN A 600 (-4.7A)","0.39A","4ckiA-2hz0A:33.5","4ckiA-2hz0A:38.39"],["4CKI_A_ADNA2022_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",6,"LEU A 251;ALA A 271;TYR A 318;GLY A 322;SER A 323;LEU A 371","None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.7A);1N8 A 501 ( 3.5A);None;1N8 A 501 ( 4.3A)","0.66A","4ckiA-2og8A:30.2","4ckiA-2og8A:40.85"],["4CKI_A_ADNA2022_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",7,"LEU A 588;GLY A 589;VAL A 596;ALA A 614;TYR A 665;GLY A 669;LEU A 785","None","0.43A","4ckiA-2ogvA:30.8","4ckiA-2ogvA:43.58"],["4CKI_A_ADNA2022_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",8,"LEU A 344;GLY A 345;GLY A 347;VAL A 352;ALA A 367;ALA A 417;GLY A 420;LEU A 468","ANP A 615 (-4.4A);ANP A 615 ( 4.4A);ANP A 615 (-3.6A);ANP A 615 (-4.5A);ANP A 615 (-3.3A);ANP A 615 (-3.9A);ANP A 615 ( 3.9A);ANP A 615 (-4.7A)","0.77A","4ckiA-2ozoA:24.0","4ckiA-2ozoA:22.51"],["4CKI_A_ADNA2022_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",7,"LEU A 344;GLY A 345;VAL A 352;ALA A 367;ALA A 417;GLY A 418;LEU A 468","ANP A 615 (-4.4A);ANP A 615 ( 4.4A);ANP A 615 (-4.5A);ANP A 615 (-3.3A);ANP A 615 (-3.9A);ANP A 615 ( 4.0A);ANP A 615 (-4.7A)","1.08A","4ckiA-2ozoA:24.0","4ckiA-2ozoA:22.51"],["4CKI_A_ADNA2022_1","2phk","Oryctolagus cuniculus","PHOSPHORYLASE KINASE","PF00069(Pkinase)",6,"LEU A  25;GLY A  26;VAL A  33;ALA A  46;GLY A 109;LEU A 156","ATP A 381 ( 4.3A);ATP A 381 (-3.5A);ATP A 381 (-4.1A);ATP A 381 (-3.5A);None;ATP A 381 ( 4.8A)","0.50A","4ckiA-2phkA:25.9","4ckiA-2phkA:27.41"],["4CKI_A_ADNA2022_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 487;GLY A 488;VAL A 495;ALA A 515;VAL A 564;TYR A 566;ALA A 567","None","0.88A","4ckiA-2psqA:38.0","4ckiA-2psqA:44.65"],["4CKI_A_ADNA2022_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 487;GLY A 490;VAL A 495;ALA A 515;TYR A 566;ALA A 567;GLY A 570","None","1.25A","4ckiA-2psqA:38.0","4ckiA-2psqA:44.65"],["4CKI_A_ADNA2022_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"LEU A 487;GLY A 493;VAL A 495;ALA A 515;VAL A 564;TYR A 566","None","0.92A","4ckiA-2psqA:38.0","4ckiA-2psqA:44.65"],["4CKI_A_ADNA2022_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",8,"LEU A 487;VAL A 495;ALA A 515;VAL A 564;TYR A 566;ALA A 567;GLY A 570;LEU A 633","None","0.46A","4ckiA-2psqA:38.0","4ckiA-2psqA:44.65"],["4CKI_A_ADNA2022_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",6,"GLY A 199;VAL A 204;ALA A 215;GLY A 271;SER A 272;LEU A 328","None;ADE A 488 ( 4.9A);ADE A 488 (-3.2A);ADE A 488 ( 4.1A);None;ADE A 488 (-4.4A)","0.43A","4ckiA-2qluA:28.5","4ckiA-2qluA:23.46"],["4CKI_A_ADNA2022_1","2qob","Homo sapiens","EPHRIN RECEPTOR","PF07714(Pkinase_Tyr)",6,"GLY A 628;GLY A 630;VAL A 635;ALA A 651;GLY A 705;LEU A 753","None;None;BME A   1 (-4.9A);PTR A 701 ( 4.7A);None;None","0.92A","4ckiA-2qobA:33.6","4ckiA-2qobA:29.29"],["4CKI_A_ADNA2022_1","2r2p","Homo sapiens","EPHRIN TYPE-A RECEPTOR 5","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"GLY A 682;GLY A 684;VAL A 689;ALA A 705;TYR A 755;GLY A 759","None","0.81A","4ckiA-2r2pA:35.7","4ckiA-2r2pA:33.13"],["4CKI_A_ADNA2022_1","2r2p","Homo sapiens","EPHRIN TYPE-A RECEPTOR 5","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"GLY A 682;VAL A 689;ALA A 705;TYR A 755;GLY A 759;LEU A 807","None","0.76A","4ckiA-2r2pA:35.7","4ckiA-2r2pA:33.13"],["4CKI_A_ADNA2022_1","2r2p","Homo sapiens","EPHRIN TYPE-A RECEPTOR 5","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"VAL A 689;ALA A 705;TYR A 755;GLY A 759;SER A 760;LEU A 807","None","0.81A","4ckiA-2r2pA:35.7","4ckiA-2r2pA:33.13"],["4CKI_A_ADNA2022_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",6,"LEU A 724;GLY A 725;VAL A 732;ALA A 749;GLY A 802;LEU A 850","GW7 A   1 ( 4.2A);None;GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);GW7 A   1 (-3.6A);GW7 A   1 (-4.2A)","0.47A","4ckiA-2r4bA:31.4","4ckiA-2r4bA:32.94"],["4CKI_A_ADNA2022_1","2wtk","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 11","PF00069(Pkinase)",6,"LEU C  55;GLY C  56;GLY C  58;VAL C  63;ALA C  76;LEU C 183","ANP C   2 ( 4.4A);ANP C   2 (-3.3A);ANP C   2 (-3.0A);ANP C   2 (-4.2A);ANP C   2 (-3.4A);None","0.83A","4ckiA-2wtkC:26.4","4ckiA-2wtkC:26.07"],["4CKI_A_ADNA2022_1","2wtk","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 11","PF00069(Pkinase)",6,"LEU C  55;GLY C  56;VAL C  63;ALA C  76;TYR C 131;LEU C 183","ANP C   2 ( 4.4A);ANP C   2 (-3.3A);ANP C   2 (-4.2A);ANP C   2 (-3.4A);None;None","0.53A","4ckiA-2wtkC:26.4","4ckiA-2wtkC:26.07"],["4CKI_A_ADNA2022_1","2x4f","Homo sapiens","MYOSIN LIGHT CHAIN KINASE FAMILY MEMBER 4","PF00069(Pkinase)",6,"LEU A 112;GLY A 113;VAL A 120;ALA A 133;TYR A 182;GLY A 186","16X A1374 (-4.1A);16X A1374 (-3.4A);16X A1374 (-4.8A);16X A1374 ( 3.8A);16X A1374 (-4.1A);16X A1374 (-4.0A)","0.82A","4ckiA-2x4fA:24.9","4ckiA-2x4fA:25.19"],["4CKI_A_ADNA2022_1","2xik","Homo sapiens","SERINE\/THREONINE PROTEIN KINASE 25","PF00069(Pkinase)",8,"GLY A  27;GLY A  29;VAL A  34;ALA A  47;TYR A  97;GLY A 101;SER A 102;LEU A 147","J60 A1294 ( 4.1A);J60 A1294 ( 4.5A);J60 A1294 ( 4.9A);J60 A1294 (-3.3A);J60 A1294 (-4.5A);J60 A1294 ( 3.8A);None;J60 A1294 (-4.8A)","0.90A","4ckiA-2xikA:22.9","4ckiA-2xikA:25.60"],["4CKI_A_ADNA2022_1","2xk9","Homo sapiens","CHECKPOINT KINASE 2","PF00069(Pkinase)",7,"LEU A 226;GLY A 227;GLY A 229;VAL A 234;ALA A 247;GLY A 307;LEU A 354","XK9 A1511 (-3.8A);XK9 A1511 ( 4.5A);None;XK9 A1511 (-4.8A);XK9 A1511 ( 4.1A);XK9 A1511 ( 3.7A);XK9 A1511 (-4.6A)","0.83A","4ckiA-2xk9A:21.9","4ckiA-2xk9A:27.12"],["4CKI_A_ADNA2022_1","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",6,"GLY A 628;VAL A 635;ALA A 651;TYR A 701;GLY A 705;LEU A 753","None;Q9G A1898 ( 4.7A);Q9G A1898 (-3.2A);Q9G A1898 (-4.8A);Q9G A1898 ( 3.8A);Q9G A1898 (-4.3A)","0.59A","4ckiA-2xyuA:27.4","4ckiA-2xyuA:34.78"],["4CKI_A_ADNA2022_1","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",6,"GLY A 628;VAL A 635;TYR A 701;GLY A 705;SER A 706;LEU A 753","None;Q9G A1898 ( 4.7A);Q9G A1898 (-4.8A);Q9G A1898 ( 3.8A);Q9G A1898 ( 4.5A);Q9G A1898 (-4.3A)","0.81A","4ckiA-2xyuA:27.4","4ckiA-2xyuA:34.78"],["4CKI_A_ADNA2022_1","2z2w","Homo sapiens","WEE1-LIKE PROTEIN KINASE","PF00069(Pkinase)",6,"GLY A 306;VAL A 313;ALA A 326;TYR A 378;GLY A 382;SER A 383","770 A 901 ( 4.6A);770 A 901 ( 4.7A);770 A 901 (-3.5A);770 A 901 (-4.2A);770 A 901 (-3.4A);None","0.65A","4ckiA-2z2wA:25.6","4ckiA-2z2wA:25.29"],["4CKI_A_ADNA2022_1","2z7r","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-1","PF00069(Pkinase)",7,"LEU A  68;GLY A  69;GLY A  71;VAL A  76;ALA A  92;GLY A 147;LEU A 194","STU A   1 (-3.8A);STU A   1 (-3.3A);STU A   1 ( 4.1A);None;STU A   1 (-3.3A);STU A   1 ( 3.9A);STU A   1 (-4.6A)","0.85A","4ckiA-2z7rA:23.3","4ckiA-2z7rA:29.49"],["4CKI_A_ADNA2022_1","2z8c","Homo sapiens","INSULIN RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A1002;GLY A1003;GLY A1005;VAL A1010;ALA A1028;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 ( 3.9A);None;S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 (-3.3A)","0.18A","4ckiA-2z8cA:36.0","4ckiA-2z8cA:40.25"],["4CKI_A_ADNA2022_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",7,"LEU A 253;GLY A 254;VAL A 261;ALA A 273;GLY A 325;SER A 326;LEU A 374","None","0.66A","4ckiA-2zv7A:15.7","4ckiA-2zv7A:35.38"],["4CKI_A_ADNA2022_1","3a62","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE BETA-1","PF00069(Pkinase)",6,"LEU A  97;GLY A  98;GLY A 100;VAL A 105;ALA A 121;TYR A 174","STU A 400 (-3.8A);STU A 400 (-3.6A);None;STU A 400 (-4.9A);STU A 400 (-3.1A);STU A 400 (-4.7A)","0.79A","4ckiA-3a62A:17.2","4ckiA-3a62A:26.81"],["4CKI_A_ADNA2022_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",10,"LEU A 487;GLY A 488;GLY A 490;VAL A 495;ALA A 515;VAL A 564;TYR A 566;ALA A 567;GLY A 570;LEU A 633","M33 A1996 (-4.0A);M33 A1996 ( 3.8A);M33 A1996 (-3.0A);M33 A1996 ( 4.7A);M33 A1996 (-3.3A);None;M33 A1996 ( 4.7A);M33 A1996 (-3.8A);M33 A1996 ( 4.8A);M33 A1996 (-4.5A)","0.72A","4ckiA-3b2tA:29.5","4ckiA-3b2tA:50.47"],["4CKI_A_ADNA2022_1","3c1x","Homo sapiens","HEPATOCYTE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"GLY A1085;GLY A1087;VAL A1092;ALA A1108;TYR A1159;GLY A1163","None;None;CKK A1500 ( 4.3A);CKK A1500 (-3.2A);CKK A1500 (-4.5A);CKK A1500 ( 4.5A)","0.90A","4ckiA-3c1xA:26.5","4ckiA-3c1xA:31.51"],["4CKI_A_ADNA2022_1","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"LEU A 484;GLY A 487;ALA A 512;VAL A 561;TYR A 563;ALA A 564;GLY A 567;LEU A 630","C4F A   1 ( 3.9A);None;C4F A   1 (-3.3A);C4F A   1 ( 4.8A);None;C4F A   1 (-3.5A);None;C4F A   1 (-4.6A)","1.21A","4ckiA-3c4fA:34.3","4ckiA-3c4fA:51.42"],["4CKI_A_ADNA2022_1","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"LEU A 484;GLY A 487;VAL A 492;ALA A 512;VAL A 561;TYR A 563;ALA A 564;LEU A 630","C4F A   1 ( 3.9A);None;None;C4F A   1 (-3.3A);C4F A   1 ( 4.8A);None;C4F A   1 (-3.5A);C4F A   1 (-4.6A)","1.25A","4ckiA-3c4fA:34.3","4ckiA-3c4fA:51.42"],["4CKI_A_ADNA2022_1","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"LEU A 484;GLY A 490;VAL A 492;ALA A 512;VAL A 561;TYR A 563;ALA A 564;LEU A 630","C4F A   1 ( 3.9A);None;None;C4F A   1 (-3.3A);C4F A   1 ( 4.8A);None;C4F A   1 (-3.5A);C4F A   1 (-4.6A)","0.78A","4ckiA-3c4fA:34.3","4ckiA-3c4fA:51.42"],["4CKI_A_ADNA2022_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",7,"GLY A 202;VAL A 209;ALA A 220;TYR A 268;GLY A 272;SER A 273;LEU A 321","None","0.38A","4ckiA-3d7uA:28.7","4ckiA-3d7uA:35.65"],["4CKI_A_ADNA2022_1","3dtc","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9","PF07714(Pkinase_Tyr)",6,"GLY A 151;VAL A 158;ALA A 169;ALA A 223;GLY A 226;LEU A 275","VIN A6331 (-3.5A);VIN A6331 (-4.7A);VIN A6331 (-3.4A);VIN A6331 (-3.8A);VIN A6331 (-3.4A);VIN A6331 (-4.5A)","0.40A","4ckiA-3dtcA:26.9","4ckiA-3dtcA:32.83"],["4CKI_A_ADNA2022_1","3eb0","Cryptosporidium parvum","PUTATIVE UNCHARACTERIZED PROTEIN","PF00069(Pkinase)",6,"LEU A  15;GLY A  16;GLY A  18;VAL A  23;ALA A  36;TYR A 119","DRK A 384 (-3.8A);DRK A 384 ( 4.4A);None;None;DRK A 384 (-3.5A);DRK A 384 (-4.4A)","0.81A","4ckiA-3eb0A:23.7","4ckiA-3eb0A:23.25"],["4CKI_A_ADNA2022_1","3fme","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","PF00069(Pkinase)",6,"LEU A  59;GLY A  60;VAL A  67;ALA A  80;SER A 135;LEU A 186","STU A   1 (-3.8A);STU A   1 (-3.5A);None;STU A   1 (-3.4A);STU A   1 (-3.2A);STU A   1 (-4.4A)","0.55A","4ckiA-3fmeA:17.8","4ckiA-3fmeA:25.74"],["4CKI_A_ADNA2022_1","3fzp","Homo sapiens","PROTEIN TYROSINE KINASE 2 BETA","PF07714(Pkinase_Tyr)",7,"LEU A 431;GLY A 432;GLY A 434;VAL A 439;ALA A 455;GLY A 508;LEU A 556","AGS A 999 ( 4.4A);AGS A 999 ( 4.2A);AGS A 999 (-3.0A);AGS A 999 (-4.6A);AGS A 999 (-3.6A);None;AGS A 999 (-4.5A)","0.85A","4ckiA-3fzpA:30.8","4ckiA-3fzpA:36.21"],["4CKI_A_ADNA2022_1","3g2f","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-2","PF00069(Pkinase)",8,"GLY A 210;GLY A 212;VAL A 217;ALA A 228;TYR A 281;GLY A 285;SER A 286;LEU A 340","ADP A 900 (-3.4A);ADP A 900 (-3.0A);ADP A 900 (-4.3A);ADP A 900 (-3.4A);None;ADP A 900 ( 4.2A);ADP A 900 (-3.6A);ADP A 900 (-4.6A)","0.78A","4ckiA-3g2fA:29.0","4ckiA-3g2fA:27.42"],["4CKI_A_ADNA2022_1","3gbz","Giardia intestinalis","KINASE, CMGC CDK","PF00069(Pkinase)",6,"LEU A  21;GLY A  22;GLY A  24;VAL A  29;ALA A  42;TYR A  93","None","0.74A","4ckiA-3gbzA:12.3","4ckiA-3gbzA:26.57"],["4CKI_A_ADNA2022_1","3gbz","Giardia intestinalis","KINASE, CMGC CDK","PF00069(Pkinase)",7,"LEU A  21;GLY A  24;VAL A  29;ALA A  42;TYR A  93;ALA A  94;LEU A 143","None","0.95A","4ckiA-3gbzA:12.3","4ckiA-3gbzA:26.57"],["4CKI_A_ADNA2022_1","3h4j","Schizosaccharomyces pombe","SNF1-LIKE PROTEIN KINASE SSP2","no annotation",6,"LEU B  40;GLY B  41;GLY B  43;VAL B  48;ALA B  61;TYR B 113","None","0.69A","4ckiA-3h4jB:15.6","4ckiA-3h4jB:27.18"],["4CKI_A_ADNA2022_1","3hdn","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE SGK1","PF00069(Pkinase)",6,"GLY A 105;GLY A 107;VAL A 112;ALA A 125;TYR A 178;LEU A 229","None;GMG A   1 (-3.3A);None;GMG A   1 (-3.4A);GMG A   1 ( 4.9A);GMG A   1 ( 4.9A)","0.86A","4ckiA-3hdnA:15.5","4ckiA-3hdnA:25.06"],["4CKI_A_ADNA2022_1","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"LEU A 833;GLY A 834;VAL A 841;ALA A 859;VAL A 909;TYR A 911;GLY A 915;LEU A1029","8ST A2001 ( 4.7A);None;8ST A2001 ( 4.6A);8ST A2001 ( 3.8A);8ST A2001 (-4.1A);8ST A2001 (-4.9A);None;None","0.68A","4ckiA-3hngA:32.4","4ckiA-3hngA:42.28"],["4CKI_A_ADNA2022_1","3iec","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK2","PF00069(Pkinase);PF00627(UBA)",6,"GLY A  60;ALA A  80;TYR A 131;ALA A 132;GLY A 135;LEU A 182","None","0.85A","4ckiA-3iecA:25.8","4ckiA-3iecA:26.59"],["4CKI_A_ADNA2022_1","3iec","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK2","PF00069(Pkinase);PF00627(UBA)",6,"GLY A  60;VAL A  67;ALA A  80;TYR A 131;ALA A 132;LEU A 182","None","0.76A","4ckiA-3iecA:25.8","4ckiA-3iecA:26.59"],["4CKI_A_ADNA2022_1","3igo","Cryptosporidium parvum","CALMODULIN-DOMAIN PROTEIN KINASE 1","PF00069(Pkinase);PF13499(EF-hand_7)",6,"LEU A  82;GLY A  83;GLY A  85;VAL A  90;ALA A 103;LEU A 205","ANP A 610 ( 4.5A);ANP A 610 (-3.5A);ANP A 610 (-2.9A);ANP A 610 (-3.9A);ANP A 610 ( 3.7A);None","0.78A","4ckiA-3igoA:20.0","4ckiA-3igoA:19.85"],["4CKI_A_ADNA2022_1","3kex","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","PF07714(Pkinase_Tyr)",7,"LEU A 696;GLY A 697;VAL A 704;TYR A 770;GLY A 774;SER A 775;LEU A 822","ANP A   1 (-4.4A);ANP A   1 (-3.7A);ANP A   1 (-3.9A);ANP A   1 (-4.3A);ANP A   1 ( 4.9A);None;ANP A   1 (-4.7A)","0.75A","4ckiA-3kexA:28.9","4ckiA-3kexA:28.37"],["4CKI_A_ADNA2022_1","3lj0","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE\/ENDORIBONUCLEASE IRE1","PF00069(Pkinase);PF06479(Ribonuc_2-5A)",6,"LEU A 680;GLY A 681;GLY A 683;VAL A 689;ALA A 700;LEU A 804","ADP A2101 ( 4.1A);ADP A2101 (-3.6A);ADP A2101 (-3.3A);ADP A2101 (-4.5A);ADP A2101 (-3.5A);ADP A2101 (-4.4A)","0.73A","4ckiA-3lj0A:25.4","4ckiA-3lj0A:23.77"],["4CKI_A_ADNA2022_1","3lm5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 17B","PF00069(Pkinase)",8,"LEU A  39;GLY A  40;VAL A  47;ALA A  60;TYR A 112;ALA A 113;GLY A 116;LEU A 165","QUE A   1 ( 3.8A);None;QUE A   1 ( 4.6A);QUE A   1 (-3.2A);QUE A   1 (-4.9A);QUE A   1 (-3.9A);None;None","0.79A","4ckiA-3lm5A:25.5","4ckiA-3lm5A:25.83"],["4CKI_A_ADNA2022_1","3lw0","Homo sapiens","INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A1005;GLY A1006;GLY A1008;VAL A1013;ALA A1031;GLY A1085","None","0.62A","4ckiA-3lw0A:30.3","4ckiA-3lw0A:39.05"],["4CKI_A_ADNA2022_1","3ma6","Toxoplasma gondii","CALMODULIN-DOMAIN PROTEIN KINASE 1","PF00069(Pkinase)",6,"LEU A  40;GLY A  41;GLY A  43;VAL A  48;ALA A  61;LEU A 164","DXR A 299 ( 4.3A);DXR A 299 ( 4.2A);DXR A 299 ( 4.1A);DXR A 299 (-4.3A);DXR A 299 ( 3.9A);None","0.83A","4ckiA-3ma6A:22.1","4ckiA-3ma6A:27.91"],["4CKI_A_ADNA2022_1","3mdy","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B","PF07714(Pkinase_Tyr);PF08515(TGF_beta_GS)",8,"GLY A 211;GLY A 213;VAL A 218;ALA A 229;TYR A 281;GLY A 285;SER A 286;LEU A 339","LDN A   1 ( 4.7A);LDN A   1 ( 4.4A);LDN A   1 ( 4.8A);LDN A   1 (-3.6A);LDN A   1 ( 4.8A);LDN A   1 (-3.3A);None;LDN A   1 (-4.5A)","0.72A","4ckiA-3mdyA:29.0","4ckiA-3mdyA:26.37"],["4CKI_A_ADNA2022_1","3mtl","Homo sapiens","CELL DIVISION PROTEIN KINASE 16","PF00069(Pkinase)",6,"LEU A 171;GLY A 172;VAL A 179;ALA A 192;TYR A 242;LEU A 293","FEF A 668 ( 3.8A);FEF A 668 ( 4.2A);FEF A 668 (-4.9A);FEF A 668 (-3.3A);FEF A 668 (-4.7A);FEF A 668 (-4.2A)","0.54A","4ckiA-3mtlA:22.4","4ckiA-3mtlA:24.53"],["4CKI_A_ADNA2022_1","3mvj","Homo sapiens","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase)",7,"LEU A  49;GLY A  50;VAL A  57;ALA A  70;TYR A 122;GLY A 126;LEU A 173","XFE A 351 (-4.2A);XFE A 351 ( 4.0A);XFE A 351 ( 4.5A);XFE A 351 (-3.2A);None;None;XFE A 351 (-4.6A)","0.69A","4ckiA-3mvjA:25.7","4ckiA-3mvjA:24.82"],["4CKI_A_ADNA2022_1","3my0","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE RECEPTOR R3","PF07714(Pkinase_Tyr)",7,"GLY A 209;VAL A 216;ALA A 227;TYR A 279;GLY A 283;SER A 284;LEU A 337","None;LDN A 600 (-4.5A);LDN A 600 (-3.2A);LDN A 600 (-4.7A);LDN A 600 (-3.3A);None;LDN A 600 (-4.6A)","0.81A","4ckiA-3my0A:27.4","4ckiA-3my0A:24.00"],["4CKI_A_ADNA2022_1","3nie","Plasmodium falciparum","MAP2 KINASE","PF00069(Pkinase)",6,"GLY A  37;GLY A  39;VAL A  44;ALA A  57;ALA A 114;LEU A 163","ANP A 430 (-3.5A);ANP A 430 (-3.0A);ANP A 430 (-4.2A);ANP A 430 (-3.5A);ANP A 430 (-3.9A);ANP A 430 (-4.4A)","0.76A","4ckiA-3nieA:23.9","4ckiA-3nieA:22.48"],["4CKI_A_ADNA2022_1","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",8,"LEU A  88;GLY A  89;GLY A  91;VAL A  96;ALA A 109;TYR A 161;ALA A 162;LEU A 212","JOZ A 361 (-4.1A);JOZ A 361 ( 4.3A);SO4 A   5 ( 4.4A);JOZ A 361 ( 4.7A);JOZ A 361 (-3.4A);None;JOZ A 361 (-3.8A);None","0.81A","4ckiA-3nuuA:26.8","4ckiA-3nuuA:27.06"],["4CKI_A_ADNA2022_1","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",8,"LEU A  88;GLY A  89;VAL A  96;ALA A 109;TYR A 161;ALA A 162;GLY A 165;LEU A 212","JOZ A 361 (-4.1A);JOZ A 361 ( 4.3A);JOZ A 361 ( 4.7A);JOZ A 361 (-3.4A);None;JOZ A 361 (-3.8A);None;None","0.74A","4ckiA-3nuuA:26.8","4ckiA-3nuuA:27.06"],["4CKI_A_ADNA2022_1","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",7,"LEU A 192;GLY A 193;GLY A 195;VAL A 200;ALA A 213;GLY A 269;LEU A 318","AMP A 577 ( 4.3A);AMP A 577 ( 3.7A);AMP A 577 (-3.4A);AMP A 577 (-4.3A);AMP A 577 (-3.4A);None;AMP A 577 (-4.8A)","0.75A","4ckiA-3nyoA:26.0","4ckiA-3nyoA:21.50"],["4CKI_A_ADNA2022_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",7,"LEU A 726;GLY A 727;GLY A 729;VAL A 734;ALA A 751;GLY A 804;LEU A 852","03Q A   1 (-3.8A);None;03Q A   1 (-3.3A);03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 ( 3.9A);03Q A   1 (-4.4A)","0.51A","4ckiA-3pp0A:34.5","4ckiA-3pp0A:31.84"],["4CKI_A_ADNA2022_1","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",7,"GLY A 558;VAL A 565;ALA A 576;TYR A 627;GLY A 631;SER A 632;LEU A 683","STU A   1 (-3.2A);STU A   1 (-4.9A);STU A   1 (-3.3A);STU A   1 (-4.4A);STU A   1 (-3.2A);STU A   1 ( 4.3A);STU A   1 (-4.3A)","0.61A","4ckiA-3ppzA:32.1","4ckiA-3ppzA:32.35"],["4CKI_A_ADNA2022_1","3q4t","Homo sapiens","ACTIVIN RECEPTOR TYPE-2A","PF00069(Pkinase)",6,"GLY A 201;VAL A 206;ALA A 217;GLY A 273;SER A 274;LEU A 329","None;TAK A   2 ( 4.9A);TAK A   2 (-3.5A);TAK A   2 (-3.6A);None;TAK A   2 (-4.6A)","0.48A","4ckiA-3q4tA:28.0","4ckiA-3q4tA:23.77"],["4CKI_A_ADNA2022_1","3qa8","Xenopus laevis","MGC80376 PROTEIN","PF00069(Pkinase)",6,"LEU A  21;GLY A  22;GLY A  24;VAL A  29;ALA A  42;TYR A  98","None","0.87A","4ckiA-3qa8A:19.5","4ckiA-3qa8A:18.77"],["4CKI_A_ADNA2022_1","3she","Homo sapiens","MAP KINASE-ACTIVATED PROTEIN KINASE 3","PF00069(Pkinase)",6,"LEU A  50;GLY A  51;GLY A  53;VAL A  58;ALA A  71;LEU A 173","I85 A 350 (-3.7A);I85 A 350 (-3.5A);I85 A 350 (-3.1A);I85 A 350 (-4.9A);I85 A 350 (-3.3A);None","0.88A","4ckiA-3sheA:20.9","4ckiA-3sheA:25.62"],["4CKI_A_ADNA2022_1","3sxf","Toxoplasma gondii","CALMODULIN-DOMAIN PROTEIN KINASE 1","PF00069(Pkinase);PF13499(EF-hand_7)",6,"LEU A  57;GLY A  58;GLY A  60;VAL A  65;ALA A  78;LEU A 181","BK5 A 701 ( 4.2A);BK5 A 701 ( 3.8A);BK5 A 701 ( 4.6A);BK5 A 701 (-4.2A);BK5 A 701 (-3.4A);None","0.65A","4ckiA-3sxfA:22.0","4ckiA-3sxfA:20.69"],["4CKI_A_ADNA2022_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",8,"LEU A 423;GLY A 424;GLY A 426;VAL A 431;ALA A 443;TYR A 491;GLY A 495;LEU A 543","PP2 A   1 (-4.1A);PP2 A   1 ( 4.1A);PP2 A   1 ( 4.8A);PP2 A   1 (-4.5A);PP2 A   1 (-3.2A);PP2 A   1 ( 4.9A);PP2 A   1 ( 4.2A);PP2 A   1 (-4.6A)","0.53A","4ckiA-3sxsA:33.6","4ckiA-3sxsA:35.22"],["4CKI_A_ADNA2022_1","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"LEU A 484;GLY A 485;GLY A 487;VAL A 492;ALA A 512;VAL A 561;TYR A 563","07J A   1 ( 4.3A);07J A   1 ( 4.9A);None;07J A   1 (-4.0A);07J A   1 (-3.5A);07J A   1 (-4.7A);07J A   1 (-4.7A)","0.78A","4ckiA-3tt0A:34.0","4ckiA-3tt0A:48.55"],["4CKI_A_ADNA2022_1","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",9,"LEU A 484;GLY A 485;VAL A 492;ALA A 512;VAL A 561;TYR A 563;ALA A 564;GLY A 567;LEU A 630","07J A   1 ( 4.3A);07J A   1 ( 4.9A);07J A   1 (-4.0A);07J A   1 (-3.5A);07J A   1 (-4.7A);07J A   1 (-4.7A);07J A   1 (-3.8A);07J A   1 (-3.7A);07J A   1 ( 4.4A)","0.67A","4ckiA-3tt0A:34.0","4ckiA-3tt0A:48.55"],["4CKI_A_ADNA2022_1","3ulz","Arabidopsis thaliana","BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1","PF00069(Pkinase)",8,"LEU A 295;GLY A 296;GLY A 298;VAL A 303;ALA A 315;TYR A 365;GLY A 369;LEU A 423","None","1.14A","4ckiA-3ulzA:26.4","4ckiA-3ulzA:27.20"],["4CKI_A_ADNA2022_1","3ulz","Arabidopsis thaliana","BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1","PF00069(Pkinase)",8,"LEU A 295;GLY A 296;VAL A 303;ALA A 315;TYR A 365;GLY A 369;SER A 370;LEU A 423","None","0.74A","4ckiA-3ulzA:26.4","4ckiA-3ulzA:27.20"],["4CKI_A_ADNA2022_1","3v5q","Homo sapiens","NT-3 GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 544;VAL A 552;ALA A 570;TYR A 619;GLY A 623;LEU A 686","0F4 A 902 ( 4.2A);None;0F4 A 902 (-3.2A);0F4 A 902 (-4.2A);0F4 A 902 (-3.4A);0F4 A 902 (-4.5A)","0.43A","4ckiA-3v5qA:30.0","4ckiA-3v5qA:37.03"],["4CKI_A_ADNA2022_1","3vid","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 840;GLY A 841;VAL A 848;ALA A 866;VAL A 916;GLY A 922;LEU A1035","4TT A2001 ( 4.0A);4TT A2001 ( 4.8A);4TT A2001 ( 4.5A);4TT A2001 (-3.5A);None;4TT A2001 (-3.7A);4TT A2001 (-4.8A)","0.61A","4ckiA-3vidA:32.0","4ckiA-3vidA:42.82"],["4CKI_A_ADNA2022_1","3vn9","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","PF00069(Pkinase)",6,"LEU A  59;GLY A  60;VAL A  67;ALA A  80;SER A 135;LEU A 186","None;ANK A 401 (-3.4A);ANK A 401 (-4.3A);ANK A 401 (-3.0A);ANK A 401 (-3.7A);ANK A 401 ( 4.9A)","0.87A","4ckiA-3vn9A:22.1","4ckiA-3vn9A:24.18"],["4CKI_A_ADNA2022_1","3w18","Homo sapiens","AURORA KINASE A","PF00069(Pkinase)",8,"LEU A 139;GLY A 140;VAL A 147;ALA A 160;TYR A 212;ALA A 213;GLY A 216;LEU A 263","N13 A 501 (-3.7A);None;N13 A 501 ( 4.7A);N13 A 501 ( 4.1A);N13 A 501 (-4.4A);N13 A 501 (-3.7A);N13 A 501 (-3.5A);N13 A 501 (-4.5A)","0.70A","4ckiA-3w18A:22.6","4ckiA-3w18A:26.20"],["4CKI_A_ADNA2022_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",7,"LEU A  75;GLY A  76;GLY A  78;VAL A  83;ALA A  96;GLY A 150;SER A 151","ANP A 401 (-3.8A);ANP A 401 ( 3.7A);ANP A 401 (-3.3A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 ( 4.3A);ANP A 401 (-3.3A)","0.84A","4ckiA-3wigA:22.5","4ckiA-3wigA:26.27"],["4CKI_A_ADNA2022_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",7,"LEU A  75;GLY A  76;VAL A  83;ALA A  96;GLY A 150;SER A 151;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 3.7A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 ( 4.3A);ANP A 401 (-3.3A);ANP A 401 (-4.8A)","0.56A","4ckiA-3wigA:22.5","4ckiA-3wigA:26.27"]]